Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

FibroGen Says CFDA Accepts Novel Anemia NDA for Review

publication date: Oct 19, 2017

FibroGen, a US-China biopharma, reported the CFDA has accepted an NDA to review its novel anemia treatment for China approval. Roxadustat is a first-in-class oral treatment for anemia in patients undergoing kidney dialysis. The China review is the first filing for the candidate. In 2013, FibroGen formed a 50/50 joint venture with AstraZeneca, which signed a $357 million deal to co-develop roxadustat in China. The China acceptance of the NDA triggers a $15 million payment to FibroGen. More details....

Stock Symbols: (NSDQ: FGEN) (NYSE: AZN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here